Darolutamide Improved Survival in Phase 3 Trials for Patients With Metastatic Hormone-Sensitive Prostate Cancer
Key Takeaways
1. Darolutamide combined with SOC therapies significantly improves progression-free and overall survival in mHSPC patients, as shown in ARANOTE and ARASENS trials.
2. The ARANOTE trial demonstrated darolutamide's superior efficacy in both high and low disease volume subgroups, reducing radiological progression or death risk.
